We narrowed to 6,313 results for: pAAV

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#26968-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 20, 2018

Academic Institutions and Nonprofits only

#137124-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-GCaMP6F (#137124). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-GCaMP6F plasmid DNA. EF1a-driven, Flp-dependent expression of GCaMP6f (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 18, 2021

Academic Institutions and Nonprofits only

#139505-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Oct. 28, 2021

Academic Institutions and Nonprofits only

#26975-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hChR2(H134R)-mCherry (#26975). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#105715-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s (#105715). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s plasmid DNA. EF1a-driven, Cre-dependent GCaMP6s fused to the presynaptic protein synaptophysin. These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

Oct. 20, 2020

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#203840-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH (#203840). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Oct. 8, 2025

Academic Institutions and Nonprofits only

#140275-AAV1

Ready-to-use AAV1 particles produced from pAAV-N-RAM-d2tTA-TRE-mKate2 (#140275). In addition to the viral particles, you will also receive purified pAAV-N-RAM-d2tTA-TRE-mKate2 plasmid DNA. RAM-containing and TRE-driven expression of mKate2. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sun et al Cell. 2020 Apr 16;181(2):410-423.e17. do

Jan. 15, 2026

Academic Institutions and Nonprofits only

#50467-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 10, 2019

Academic Institutions and Nonprofits only

#83894-AAV5

Ready-to-use AAV5 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Sept. 27, 2023

Academic Institutions and Nonprofits only

#59133-AAV1

Ready-to-use AAV1 particles produced from pOTTC589 - pAAV c-fos Nuc-eYFP (#59133). In addition to the viral particles, you will also receive purified pOTTC589 - pAAV c-fos Nuc-eYFP plasmid DNA. C-fos-driven expression of Nuc-eYFP. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Richie et al J Neurosci Methods. 2017 Jun 1;284:1-14.

Jan. 15, 2026

Academic Institutions and Nonprofits only

#83894-AAV9

Ready-to-use AAV9 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 2, 2020

Academic Institutions and Nonprofits only

#198516-AAV5

Ready-to-use AAV5 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#124651-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 (#124651). In addition to the viral particles, you will also receive purified pAAV-CamKIIa-ChrimsonR-mScarlet-KV2.1 plasmid DNA. CamKIIa-driven expression of ChrimsonR fused to mScarlet fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Aug. 7, 2025

Academic Institutions and Nonprofits only

#83894-AAV1

Ready-to-use AAV1 particles produced from pAAV-hDlx-Flex-dTomato-Fishell_7 (#83894). In addition to the viral particles, you will also receive purified pAAV-hDlx-Flex-dTomato-Fishell_7 plasmid DNA. hDlx-driven, Cre-dependent expression of dTomato. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Aug. 28, 2020

Academic Institutions and Nonprofits only

#50467-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine (#50467). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. CaMKIIa-driven HA-tagged hM4D(Gi) and bicistronic mCitrine expression, for chemogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2020

Academic Institutions and Nonprofits only

#139505-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#26972-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-eNpHR 3.0-EYFP (#26972). In addition to the viral particles, you will also receive purified pAAV-hSyn-eNpHR 3.0-EYFP plasmid DNA. hSyn-driven eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Aug. 7, 2025

Academic Institutions and Nonprofits only

#137129-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-BFP (#137129). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-BFP plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of BFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 8, 2021

Academic Institutions and Nonprofits only